Kyverna Therapeutics Inc. (KYTX)
KYTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | KYTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001994702 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $31.8M cash; operating cash flow -$37.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 63,221,970 (2026-11-06); 43,796,170 a year earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-04-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1000K, sold $293K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$41.9M | -$35.4M | $31.8M | $25.0M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$38.3M | -$40.3M | $31.8M | $24.9M | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$39.7M | -$41.6M | $32.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$37.8M | -$33.5M | $124.1M | $24.7M | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$36.8M | -$43.3M | $34.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$42.1M | -$31.9M | $53.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$44.6M | -$44.9M | $56.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$37.5M | -$37.1M | $96.6M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-02 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-13 |
Source: SEC EDGAR submissions feed, 190 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.5% |
| 1 month | -12.5% |
| 3 months | -37.5% |
| Year to date | -46.3% |
| 1 year | -22.1% |
| From 52-week high | -55.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.14 | -2.56% | $303.6M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
| AGMB | AgomAb Therapeutics NV | $5.97 | -6.13% | $294.0M |
| EIKN | Eikon Therapeutics Inc. | $5.38 | -9.95% | $291.8M |
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier